NuVasive (NASDAQ: NUVA) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its peers? We will compare NuVasive to related companies based on the strength of its risk, analyst recommendations, profitability, earnings, valuation, institutional ownership and dividends.

Profitability

This table compares NuVasive and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NuVasive 3.50% 13.04% 5.81%
NuVasive Competitors -127.18% -36.38% -10.25%

Earnings and Valuation

This table compares NuVasive and its peers top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
NuVasive $1.02 billion $225.78 million 88.66
NuVasive Competitors $827.23 million $159.50 million 41.55

NuVasive has higher revenue and earnings than its peers. NuVasive is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings for NuVasive and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NuVasive 1 2 11 0 2.71
NuVasive Competitors 175 1138 2486 89 2.64

NuVasive currently has a consensus target price of $74.00, indicating a potential upside of 34.62%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.68%. Given NuVasive’s stronger consensus rating and higher probable upside, research analysts clearly believe NuVasive is more favorable than its peers.

Volatility and Risk

NuVasive has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, NuVasive’s peers have a beta of 1.06, indicating that their average stock price is 6% more volatile than the S&P 500.

Institutional and Insider Ownership

66.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 1.2% of NuVasive shares are held by insiders. Comparatively, 10.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

NuVasive beats its peers on 8 of the 13 factors compared.

About NuVasive

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.